Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1995 Dec;59(6):597–600. doi: 10.1136/jnnp.59.6.597

Clinical and [18F] dopa PET findings in early Parkinson's disease.

P K Morrish 1, G V Sawle 1, D J Brooks 1
PMCID: PMC1073753  PMID: 7500096

Abstract

Twenty seven patients with recent onset (mean symptom duration 22 (SD 14) months, Hoehn and Yahr score 1.8 (SD 0.7)) Parkinson's disease were studied with [18F]dopa PET. There was a correlation between putamen influx (Ki) and clinical rating, but not symptom duration. In 11 patients with hemi-Parkinson's disease of recent onset there were significant differences between normal (mean 0.0123 (SD 0.0023)), asymptomatic (mean 0.0099 (0.0020)) and symptomatic (mean 0.0070 (00.014)) putamen Kis. This suggests that Parkinson's disease has a widely variable rate of progression, and is most compatible with a short preclinical period. Symptom onset was estimated at a putamen Ki of between 57% and 80% of normal. Most ipsilateral putamen Ki values in early asymmetric Parkinson's disease fell within the normal range. The implication is that either the disease is not established in the ipsilateral putamen or that the technique is insufficiently sensitive to detect it. Discriminant analysis completely separated the normal and Parkinson's disease cohorts, but when a discriminant function from a previous study was used predictively four of the 27 patients with Parkinson's disease were incorrectly classified as normal.

Full text

PDF
597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  2. Boyes B. E., Cumming P., Martin W. R., McGeer E. G. Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects. Life Sci. 1986 Dec 8;39(23):2243–2252. doi: 10.1016/0024-3205(86)90403-0. [DOI] [PubMed] [Google Scholar]
  3. Brooks D. J. Detection of preclinical Parkinson's disease with PET. Neurology. 1991 May;41(5 Suppl 2):24–28. doi: 10.1212/wnl.41.5_suppl_2.24. [DOI] [PubMed] [Google Scholar]
  4. Brooks D. J., Salmon E. P., Mathias C. J., Quinn N., Leenders K. L., Bannister R., Marsden C. D., Frackowiak R. S. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990 Oct;113(Pt 5):1539–1552. doi: 10.1093/brain/113.5.1539. [DOI] [PubMed] [Google Scholar]
  5. Burn D. J., Mark M. H., Playford E. D., Maraganore D. M., Zimmerman T. R., Jr, Duvoisin R. C., Harding A. E., Marsden C. D., Brooks D. J. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 1992 Oct;42(10):1894–1900. doi: 10.1212/wnl.42.10.1894. [DOI] [PubMed] [Google Scholar]
  6. Eidelberg D., Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Margouleff D., Moeller J. R., Patlak C. S., Fahn S. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993 Sep;13(5):881–888. doi: 10.1038/jcbfm.1993.110. [DOI] [PubMed] [Google Scholar]
  7. Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5):2283–2301. doi: 10.1093/brain/114.5.2283. [DOI] [PubMed] [Google Scholar]
  8. German D. C., Manaye K., Smith W. K., Woodward D. J., Saper C. B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol. 1989 Oct;26(4):507–514. doi: 10.1002/ana.410260403. [DOI] [PubMed] [Google Scholar]
  9. Gibb W. R., Lees A. J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745–752. doi: 10.1136/jnnp.51.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goto S., Hirano A., Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol. 1989 Dec;26(6):766–770. doi: 10.1002/ana.410260613. [DOI] [PubMed] [Google Scholar]
  11. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  12. Koller W. C., Langston J. W., Hubble J. P., Irwin I., Zack M., Golbe L., Forno L., Ellenberg J., Kurland L., Ruttenber A. J. Does a long preclinical period occur in Parkinson's disease? Neurology. 1991 May;41(5 Suppl 2):8–13. [PubMed] [Google Scholar]
  13. Pate B. D., Kawamata T., Yamada T., McGeer E. G., Hewitt K. A., Snow B. J., Ruth T. J., Calne D. B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol. 1993 Sep;34(3):331–338. doi: 10.1002/ana.410340306. [DOI] [PubMed] [Google Scholar]
  14. Patlak C. S., Blasberg R. G., Fenstermacher J. D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983 Mar;3(1):1–7. doi: 10.1038/jcbfm.1983.1. [DOI] [PubMed] [Google Scholar]
  15. Robb R. A., Hanson D. P. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med. 1991 Mar;14(1):9–30. [PubMed] [Google Scholar]
  16. Sawle G. V., Burn D. J., Morrish P. K., Lammertsma A. A., Snow B. J., Luthra S., Osman S., Brooks D. J. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology. 1994 Jul;44(7):1292–1297. doi: 10.1212/wnl.44.7.1292. [DOI] [PubMed] [Google Scholar]
  17. Sawle G. V., Colebatch J. G., Shah A., Brooks D. J., Marsden C. D., Frackowiak R. S. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol. 1990 Dec;28(6):799–804. doi: 10.1002/ana.410280611. [DOI] [PubMed] [Google Scholar]
  18. Sawle G. V., Playford E. D., Burn D. J., Cunningham V. J., Brooks D. J. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol. 1994 Mar;51(3):237–243. doi: 10.1001/archneur.1994.00540150027011. [DOI] [PubMed] [Google Scholar]
  19. Scott R. M., Brody J. A., Schwab R. S., Cooper I. S. Progression of unilateral tremor and rigidity in Parkinson's disease. Neurology. 1970 Jul;20(7):710–714. doi: 10.1212/wnl.20.7.710. [DOI] [PubMed] [Google Scholar]
  20. Snow B. J., Tooyama I., McGeer E. G., Yamada T., Calne D. B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993 Sep;34(3):324–330. doi: 10.1002/ana.410340304. [DOI] [PubMed] [Google Scholar]
  21. Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Zanzi I., Mandel F., Spetsieris P., Eidelberg D. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. J Nucl Med. 1994 Jun;35(6):955–963. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES